GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BSP:AMGN34) » Definitions » Short-Term Debt

Amgen (BSP:AMGN34) Short-Term Debt : R$19,626 Mil (As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Amgen Short-Term Debt?

Amgen's Short-Term Debt for the quarter that ended in Sep. 2024 was R$19,626 Mil.

Amgen's quarterly Short-Term Debt increased from Mar. 2024 (R$19,715 Mil) to Jun. 2024 (R$29,774 Mil) but then declined from Jun. 2024 (R$29,774 Mil) to Sep. 2024 (R$19,626 Mil).

Amgen's annual Short-Term Debt increased from Dec. 2021 (R$492 Mil) to Dec. 2022 (R$8,345 Mil) but then declined from Dec. 2022 (R$8,345 Mil) to Dec. 2023 (R$7,070 Mil).


Amgen Short-Term Debt Historical Data

The historical data trend for Amgen's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Short-Term Debt Chart

Amgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,120.59 468.17 491.98 8,345.43 7,070.41

Amgen Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,052.46 7,070.41 19,715.03 29,774.36 19,625.96

Amgen Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Amgen Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Amgen's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen Business Description

Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Headlines

No Headlines